Calendar

This webinar highlights an introduction to Scholar Rock, an emerging biopharmaceutical company, and provides an overview of the Spinal Muscular Atrophy (SMA) disease landscape, remaining unmet needs in SMA, and apitegromab clinical data.

Advance understanding of the importance of frequent monitoring risk level of pulmonary arterial hypertension (PAH) and right heart monitoring. Explore and discuss the importance of timely escalation of therapies in the treatment of PAH. Participants will learn about the significant role risk stratification plays in informing providers' treatment decisions, as well as the importance of right heart and hemodynamic considerations in conjunction with risk assessment.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Crohn's disease and ulcerative colitis are chronic autoimmune disorders associated with major clinical and economic burden. The American College of Gastroenterology (ACG) recently released updates to their clinical guidelines for the Management of Crohn's Disease (CD) and Ulcerative Colitis (UC) in Adults. Both guidelines incorporate available evidence to provide recommendations for the treatment and prevention of complications associated with inflammatory bowel disease (IBD). The objective of this webinar is to highlight guideline updates and provide suggestions for application of the recommendations into practice and payer policy.

IgA nephropathy is an autoimmune, progressive, chronic kidney disease characterized by pathogenic IgA accumulation and immune complex formation in the glomerulus, causing inflammation and progressive kidney damage. The webinar will review IgA nephropathy and clinical outcomes from Phase 2 and 3 trials of an investigational product that is under clinical evaluation for the treatment of primary IgA nephropathy in adults. Efficacy and safety have not yet been established.

Reliable drug information is the backbone of safe and effective patient care. It's what helps make informed decisions, optimize therapeutic outcomes, and confidently navigate the complex healthcare landscape. For early-career professionals, knowing where to find trusted, evidence-based resources - like drug databases and clinical decision-support tools - can be a real game-changer.

Are you a student, new practitioner, or professional considering a transition into managed care pharmacy? Join AMCP on Tuesday, September 24 at 7:00 pm ET for an engaging webinar that will introduce you to the foundations of managed care pharmacy, the diverse roles available, and the real-world impact managed care pharmacists have on patients, health plans, and the health care system.

This session is designed for those exploring career options, looking to expand their professional opportunities, or seeking a better work-life balance in a growing field. You'll learn how managed care pharmacists shape formularies, influence evidence-based coverage decisions, improve medication access, and drive value-based care - all while keeping patients at the center. Whether you're just beginning your career or considering a new direction, this program will provide insights to help you envision your future in managed care pharmacy.

Chronic Lymphocytic Leukemia (CLL) is a complex, indolent blood cancer in which immature lymphocytes are found mostly in the blood and bone marrow. It is the most common type of leukemia in adults, affecting an estimated 226,432 people in the United States as of 2022. The entry of Bruton’s tyrosine kinase inhibitors (BTKis) into the treatment landscape caused a shift to more targeted oral therapy. The cost of treatment and medically managing CLL patients within the US healthcare system is of particular interest for healthcare decision makers. The objective of this webinar is to explore the results of a cost-effectiveness analyses of covalent BTKis in first-line (1L) or relapsed/refractory (R/R) settings using data from clinical trials and the US Medicare perspective.

By the end of this session, attendees will be able to:

• Recognize the significant unmet medical need in the Macular Telangiectasia Type 2 (MacTel), including clinical characteristics, disease progression and implications of delayed or absent treatment.
• Understand the patient journey where patients often navigate through subtle, inconsistent symptoms that affect their activities of daily living and quality of life prior to obtaining a definitive diagnosis.
• Explain the mechanism of action, clinical efficacy, safety profile, and long-term durability of ENCELTO, emphasizing the cell-based gene therapy's ability to address the underlying pathophysiology of MacTel.
• Assess key factors impacting patient access to ENCELTO and potential solutions to balance affordability concerns with appropriate access to treatment.

Significant policy changes under the new presidential administration are set to impact various healthcare sectors. Upstream influences demand a strategic reevaluation of global supply chains and competitive positioning, while downstream effects will reshape how organizations and communities engage with and serve local populations.

This session will examine the evolving policy landscape and its implications for stakeholders in managed care pharmacy and the biopharmaceutical industry. Through expert insights and dynamic discussion, attendees will gain a practical framework to navigate emerging challenges and opportunities, empowering informed decision-making in a rapidly changing healthcare environment.

Migraine is a complex, chronic disease that results in significant patient and economic burden. Migraine ranks second worldwide in terms of years lost due to disability. Direct annual all cause healthcare costs for a migraine patient is over twice that of a non-migraine patient. Indirect costs from the impact of the disease on a patient's ability to function (absenteeism and presenteeism) total over $35B annually.

Therefore, it is important to appropriately manage a person with migraine who experiences greater than 4 attacks a month (or severe disability from at least two attacks a month) and may benefit from preventive therapy. One of the main goals of preventive therapy is to improve function and reduce disability. Utilizing a stratified care approach to preventive migraine treatment is key to accomplish this goal.